News & Information

CoM3D and University of Texas at Austin sign patent license agreement

The University of Texas at Austin and CoM3D Limited, a company focused on commercialization of advanced drug manufacturing and...

CoM3D logo
CoM3D Secures up to £1M in New Funding

CoM3D is very pleased to announce the successful closing of a recently announced financing round, having secured up to £1M...

CoM3D developing hybrid anti-viral delivery systems

CoM3D is pleased to announce its work on the development of hybrid anti-viral nanoparticulate delivery systems, has commenced, at the University of Texas...

Maniruzzaman Lab collaboration works to develop patient-focused medicines more efficiently

In an effort to address challenges with the reduction in quantity of new drugs coming to market, a team of pharmaceutical scientists...

CoM3D appoints Alastair Syvret to Advisory Panel

CoM3D are pleased to announce the appointment of Alastair Syvret to it's Advisory Panel. From 1995 to 2018 Alastair was a partner of...

CoM3D launches Funding Round

CoM3D is delighted to announce the launch of a funding round to enable larger scale funding of its R&D efforts at the University of Texas at Austin...

CoM3D appoints Dr Anthony Thomson as CEO

CoM3D are delighted to announce the appointment of Dr Anthony Thomson MSc MBA PhD FRSM as CEO of the company which is working...

Video Highlights


3D Printing of thin film, smart biomaterials

Rapidly Dissolving PortaPill

Twitter Logo